-
Mashup Score: 1
Patients with advanced hepatocellular carcinoma who were treated with lenvatinib following progression on immunotherapy had a median overall survival of 12.8 months and progression-free survival of 3.7 months.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Dr Wirth reviews the updated NCCN guidelines that gave lenvatinib a category 1 recommendation for first-line treatment in advanced RAI-R-DTC and shares her experience of lenvatinib in clinical practice.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Wirth reviews the updated @NCCN guidelines that gave lenvatinib a category 1 recommendation for first-line treatment in advanced RAI-R-DTC and shares her experience of #lenvatinib in clinical practice. #thycsm | @MGHCancerCenter https://t.co/4PaZPyYejV
-
-
Mashup Score: 0
During a Targeted Oncology case-based roundtable event, Amit Singal, MD, discussed the data from the LEAP-002 trial of lenvatinib/pembrolizumab vs lenvatinib in patients with hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Amit Singal, MD, discussed the data from the LEAP-002 trial of #lenvatinib/#pembrolizumab vs lenvatinib in patients with hepatocellular carcinoma. #HCC #lcsm | @UTSWHospitalMed @UTSWNews @utswcancer @docamitgs https://t.co/Y955lKCLCL
-
-
Mashup Score: 0
During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During a live virtual event, @GABOUALFA, MD, discussed the results of the REFLECT trial of #lenvatinib vs #sorafenib and the LEAP-002 trial of lenvatinib/#pembrolizumab vs lenvatinib in patients with hepatocellular carcinoma. #lcsm #HCC | @MSKCancerCenter https://t.co/6fLE0Xl33W
-
-
Mashup Score: 0
Dr Worden reviews and discusses real-world data of lenvatinib monotherapy in patients with radioiodine-refractory differentiated thyroid cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Watch: Francis Paul Worden, MD, of @UMRogelCancer, reviews and discusses real-world data of #lenvatinib monotherapy in patients with radioiodine-refractory differentiated thyroid cancer. #oncology #medtwitter https://t.co/T17UAI4y5h
-
-
Mashup Score: 0Managing Adverse Events of Lenvatinib in Patients with RAI-R-DTC - 1 year(s) ago
A key opinion leader explains the adverse events usually seen with lenvatinib treatment in patients with RAI-R-DTC, and the best management strategies.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A key opinion leader explains the adverse events usually seen with #lenvatinib treatment in patients with RAI-R-DTC, and the best management strategies. #thycsm | @MGHCancerCenter https://t.co/mU7jSy6M8q
-
-
Mashup Score: 0
Dr Lori Wirth reviews real-world outcomes data on lenvatinib treatment in patients with RAI-R-DTC and how they compare to the SELECT trial.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr Lori Wirth reviews real-world outcomes data on #lenvatinib treatment in patients with RAI-R-DTC and how they compare to the SELECT trial. #thycsm | @MGHMedicine @MassGeneralNews https://t.co/yekOnR4sg1
-
-
Mashup Score: 0
The newly launched phase 2 LenCabo study of lenvatinib with everolimus vs cabozantinib for the second- or third-line treatment of metastatic renal cell carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The newly launched phase 2 #LenCabo study of #lenvatinib with #everolimus vs #cabozantinib for the second- or third-line treatment of metastatic renal cell carcinoma. #RCC #kcsm #IKCS22 https://t.co/Uw0pJHNd6K
-
-
Mashup Score: 0Pembrolizumab and Lenvatinib Approval Opens New Door in Endometrial Cancer Treatment - 1 year(s) ago
Wesley Burkett, MD, adiscusses his excitement for the approval of pembrolizumab in combination with lenvatinib for patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Wesley Burkett, MD, discusses his excitement for the approval of #pembrolizumab in combination with #lenvatinib for patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient. #gyncsm | @UNC_SOM https://t.co/SOOa0YcYBQ
-
-
Mashup Score: 0
During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During a live virtual event, @GABOUALFA, MD, discussed the results of the REFLECT trial of #lenvatinib vs #sorafenib and the LEAP-002 trial of lenvatinib/#pembrolizumab vs lenvatinib in patients with hepatocellular carcinoma. #lcsm #HCC | @MSKCancerCenter https://t.co/6fLE0Xl33W
-
#Lenvatinib following progression on immunotherapy may have survival benefit for patients with advanced hepatocellular carcinoma, according to findings presented at #GI23. #gicsm #HCC | @MayoCancerCare @jennifer_gile https://t.co/DQKrQEbD8K